Login

Access type

Forgot your password? Click here

LOGIN
Annulla
Forgot
DMP_ForgotOK Close

REGISTER

If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.

REGISTER
A A A
Contacts
Follow LinkedIn YouTube

Dompé at a glance

Excellence in therapeutic innovation

Dompé is an Italian biopharmaceutical company that focuses on innovation, where a long tradition in the field of healthcare goes hand in hand with a commitment to research and development to meet hitherto unsatisfied therapeutic needs. A challenge that the Company has pursued with passion, skill and courage, to make a difference to the lives of people around the globe.

An international presence

Founded in 1940, Dompé has its headquarters in Milan, major industrial and biotechnological research facilities in L’Aquila, and an R&D unit in Naples.

The Company has offices also in Barcelona, Slough (UK), Paris and Berlin.

Innovation that supports research

Dompé concentrates on areas with still unsatisfied therapeutic needs, such as diabetes, organ transplantation, ophthalmology and oncology. The company is strongly committed in this field with 21 clinical studies in progress involving a total of 1,200 patients and 200 research centres worldwide. In 2017 Dompé expects a 250 million euro turnover, of which 15% will be invested in R&D.

Key partnerships

In line with its mission, Dompé supports companies that demonstrate a high level of dynamism in healthcare innovation, and particularly in biotechnologies.

  • From 2011 majority shareholder of Philogen, an Italian-Swiss biotech company specialized in biopharmaceutical products for the treatment of cancer, rheumatoid arthritis and some ophthalmic diseases.
  • In 2012, it acquired Anabasis, an Italian biotech company that develops innovative drugs based on rhNGF (the discovery of which led to Prof. Rita Levi Montalcini being awarded the Nobel Prize) for the treatment of serious eye diseases for which no effective therapy is currently available.
  • In the same year, it became the leading shareholder in AAA (Advanced Accelerator Applications), a leader in the field of molecular medicine that specialises in R&D, the production of radiopharmaceuticals for molecular imaging, and personalised medicine.